FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2002605983> ?p ?o ?g. }

• W2002605983 endingPage "2288" @default.
• W2002605983 startingPage "2279" @default.
• W2002605983 abstract "We compared a relatively short regimen of monochemotherapy with epirubicin versus polychemotherapy with CMF (cyclophosphamide, methotrexate, 5-fluorouracil) as adjuvant treatment for stage I and II breast cancer patients. 348 patients with oestrogen receptor negative (ER-) node negative and ER- or ER+ node-positive with <10 nodes were accrued. CMF was given intravenously (i.v.) on days 1 and 8, every 4 weeks, for six courses; epirubicin was given weekly for 4 months. Postmenopausal patients received tamoxifen for 3 years. The primary endpoints were overall survival (OS), relapse-free survival (RFS) and event-free survival (EFS). Outcome evaluation was performed both in eligible patients and in all randomised patients according to the intention-to-treat principle. 8 randomised patients were considered ineligible. At a median follow-up of 8 years, there was no difference in OS (Hazard Ratio (HR)=1.11, 95% Confidence Interval (CI): 0.77-1.61, P=0.58), EFS (HR=1.14, 95% CI: 0.78-1.64, P=0.48), and RFS (HR=1.14, 95% CI: 0.8-1.64, P=0.48) between the two arms for all of the patients. At 8 years, the RFS percentages (+/-Standard Error (S.E.)) were 65.4% (+/-4%) in the CMF arm and 62.7% (+/-4%) in the epirubicin arm; for EFS these were 64.2% (+/-4%) for CMF and 60.8% (+/-4%) for epirubicin, respectively. A significant difference in RFS (P=0.015) was observed in patients with 4-9 positive nodes in favour of the CMF arm. Toxicity in the two arms was superimposable except for more frequent grade 3 alopecia in the epirubicin-treated patients (P=0.001). Overall, at a median follow-up of 8 years, there were no differences between the two arms in terms of OS, EFS and RFS." @default.
• W2002605983 created "2016-06-24" @default.
• W2002605983 creator A5005319110 @default.
• W2002605983 creator A5011624962 @default.
• W2002605983 creator A5015744186 @default.
• W2002605983 creator A5022206145 @default.
• W2002605983 creator A5026459926 @default.
• W2002605983 creator A5034104978 @default.
• W2002605983 creator A5038784620 @default.
• W2002605983 creator A5048969389 @default.
• W2002605983 creator A5060297610 @default.
• W2002605983 creator A5060304557 @default.
• W2002605983 creator A5066793236 @default.
• W2002605983 creator A5067193136 @default.
• W2002605983 creator A5068497911 @default.
• W2002605983 creator A5079039762 @default.
• W2002605983 creator A5081042999 @default.
• W2002605983 creator A5082264441 @default.
• W2002605983 date "2002-11-01" @default.
• W2002605983 modified "2023-09-27" @default.
• W2002605983 title "Epirubicin versus CMF as adjuvant therapy for stage I and II breast cancer: a prospective randomised study" @default.
• W2002605983 cites W120612427 @default.
• W2002605983 cites W12356482 @default.
• W2002605983 cites W1262485082 @default.
• W2002605983 cites W1536690700 @default.
• W2002605983 cites W1547732034 @default.
• W2002605983 cites W1580788756 @default.
• W2002605983 cites W1848579801 @default.
• W2002605983 cites W1860873974 @default.
• W2002605983 cites W1863343593 @default.
• W2002605983 cites W1882532563 @default.
• W2002605983 cites W1888375872 @default.
• W2002605983 cites W1899541887 @default.
• W2002605983 cites W1929485622 @default.
• W2002605983 cites W1946018534 @default.
• W2002605983 cites W1962532604 @default.
• W2002605983 cites W1974247223 @default.
• W2002605983 cites W1979300931 @default.
• W2002605983 cites W2010014361 @default.
• W2002605983 cites W2028269517 @default.
• W2002605983 cites W206480088 @default.
• W2002605983 cites W2075698581 @default.
• W2002605983 cites W2079487121 @default.
• W2002605983 cites W2091264604 @default.
• W2002605983 cites W2139984188 @default.
• W2002605983 cites W2146478870 @default.
• W2002605983 cites W2152476861 @default.
• W2002605983 cites W2172570236 @default.
• W2002605983 cites W2214029008 @default.
• W2002605983 cites W2220950919 @default.
• W2002605983 cites W2226691778 @default.
• W2002605983 cites W2235063564 @default.
• W2002605983 cites W2261337567 @default.
• W2002605983 cites W2270235662 @default.
• W2002605983 cites W2283947545 @default.
• W2002605983 cites W2335332412 @default.
• W2002605983 cites W2399481698 @default.
• W2002605983 cites W2405002147 @default.
• W2002605983 cites W2597616474 @default.
• W2002605983 cites W2797177778 @default.
• W2002605983 cites W2029496089 @default.
• W2002605983 cites W2313308602 @default.
• W2002605983 doi "https://doi.org/10.1016/s0959-8049(02)00452-5" @default.
• W2002605983 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12441265" @default.
• W2002605983 hasPublicationYear "2002" @default.
• W2002605983 type Work @default.
• W2002605983 sameAs 2002605983 @default.
• W2002605983 citedByCount "15" @default.
• W2002605983 countsByYear W20026059832012 @default.
• W2002605983 crossrefType "journal-article" @default.
• W2002605983 hasAuthorship W2002605983A5005319110 @default.
• W2002605983 hasAuthorship W2002605983A5011624962 @default.
• W2002605983 hasAuthorship W2002605983A5015744186 @default.
• W2002605983 hasAuthorship W2002605983A5022206145 @default.
• W2002605983 hasAuthorship W2002605983A5026459926 @default.
• W2002605983 hasAuthorship W2002605983A5034104978 @default.
• W2002605983 hasAuthorship W2002605983A5038784620 @default.
• W2002605983 hasAuthorship W2002605983A5048969389 @default.
• W2002605983 hasAuthorship W2002605983A5060297610 @default.
• W2002605983 hasAuthorship W2002605983A5060304557 @default.
• W2002605983 hasAuthorship W2002605983A5066793236 @default.
• W2002605983 hasAuthorship W2002605983A5067193136 @default.
• W2002605983 hasAuthorship W2002605983A5068497911 @default.
• W2002605983 hasAuthorship W2002605983A5079039762 @default.
• W2002605983 hasAuthorship W2002605983A5081042999 @default.
• W2002605983 hasAuthorship W2002605983A5082264441 @default.
• W2002605983 hasConcept C121608353 @default.
• W2002605983 hasConcept C126322002 @default.
• W2002605983 hasConcept C143998085 @default.
• W2002605983 hasConcept C207103383 @default.
• W2002605983 hasConcept C2776694085 @default.
• W2002605983 hasConcept C2776755627 @default.
• W2002605983 hasConcept C2777176818 @default.
• W2002605983 hasConcept C2780835546 @default.
• W2002605983 hasConcept C2781413609 @default.
• W2002605983 hasConcept C44249647 @default.
• W2002605983 hasConcept C530470458 @default.
• W2002605983 hasConcept C71924100 @default.

• next